Polysaccharide vaccine for staphylococcal infections

Abstract

The present invention relates to compositions of staphylococcal deacetylated poly-N-acetylglucosamine (dPNAG). Deacetylated poly-N-acetylglucosamine can be isolated from natural sources or synthesized de novo. The present invention also relates to the use of deacetylated poly-N-acetylglucosamine as a vaccine to induce resistance to Staphylococcus aureus, Staphylococcus epidermidis, other related coagulase-negative or coagulase-positive staphylococci, and other carrier intracellular Active immunity to infection by organisms attached to loci. The present invention also provides a method for using the antibody targeting deacetylated poly-N-acetylglucosamine, especially a method for inducing passive immunity against similar infections.

Description

Field of Invention

[0001] The present invention relates to immune-inducing polysaccharide compositions for the prevention and treatment of staphylococcal infection. The present invention also relates to methods for preparing and using polysaccharide-based antigens, related antibodies and diagnostic kits, and methods for inducing active and passive immunity by using polysaccharide materials and antibodies thereof. Background of the Invention

[0002] Staphylococci are Gram-positive bacteria that normally inhabit and colonize human skin and mucous membranes. If the skin or mucous membranes are damaged during surgery or other trauma, staph bacteria have the opportunity to enter the internal tissues, causing the infection to worsen. If staphylococci proliferate locally or enter the lymphatic or blood system, serious infectious complications, such as those associated with staphylococcal bacteremia, can result. These complications include septic shock, endocarditis, arthritis, o...

Images